tiprankstipranks

China Shineway Reports 2024 Revenue Decline Amid TCM Industry Challenges

Story Highlights
China Shineway Reports 2024 Revenue Decline Amid TCM Industry Challenges

Elevate Your Investing Strategy:

An announcement from China Shineway Pharmaceutical Group Limited ( (HK:2877) ) is now available.

China Shineway Pharmaceutical Group Limited reported a 16.4% decrease in sales revenue for 2024, with a net profit decline of 13.4%, reflecting challenges in the TCM industry due to policy changes and market competition. Despite these challenges, the company maintained stable profitability by optimizing production processes and enhancing market competitiveness. The TCM industry is poised for growth with national support and reforms, offering new opportunities for transformation and development.

More about China Shineway Pharmaceutical Group Limited

China Shineway Pharmaceutical Group Limited operates in the pharmaceutical industry, focusing on traditional Chinese medicine (TCM) products. The company is involved in the production and distribution of TCM and formula granules, with a market focus on enhancing the TCM industry chain and adapting to evolving healthcare policies.

YTD Price Performance: -10.16%

Average Trading Volume: 1,103,118

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$6.4B

See more data about 2877 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1